NEW YORK, January 8, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Eli Lilly & Co. (NYSE :LLY ), Allergan Inc. (NYSE :AGN ), Waters Corp. (NYSE :WAT ), Novavax, Inc. (NASDAQ :NVAX ), and Supernus Pharmaceuticals, Inc. (NASDAQ :SUPN ). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Eli Lilly & Co. Research Report
On January 2, 2014, Eli Lilly & Co. (Lilly) reported that it will announce its 2014 financial guidance and financial results for Q4 2013 and full year of 2013, on January 7, 2014 and January 30, 2014, respectively. The Company stated that it will also hold conference calls with the investment community and media to further discuss its 2014 financial guidance and its 2013 financial performance, respectively, on both days at 9:00 a.m. EST. Lilly added that live webcasts of the calls can be accessed via the Company website. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Allergan Inc. Research Report
On January 3, 2014, Allergan Inc.'s (Allergan) stock climbed 1.61%, ending the day at $112.06. Over the previous three trading sessions, shares of Allergan rose 1.18%, compared to the Dow Jones industrial average, which declined 0.21% during the same period. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Waters Corp. Research Report
On January 3, 2014, Waters Corp.'s (Waters) stock declined 1.19%, ending the day at $98.04. Over the previous three trading sessions, shares of Waters fell 2.25%, compared to the Dow Jones industrial average which declined 0.21% during the same period. The Full Research Report on Waters Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Novavax, Inc. Research Report
On January 3, 2014, Novavax, Inc.'s (Novavax) stock rose 1.92%, ending the day at $5.31. Over the previous three trading sessions, shares of Novavax climbed 2.91%, compared to the Nasdaq Composite which declined 0.54% during the same period. The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Supernus Pharmaceuticals, Inc. Research Report
On December 24, 2013, Supernus Pharmaceuticals, Inc. (Supernus) announced the resignation of Michael Bigham, a General Partner at Abingworth, from the Company's Board of Directors, effective December 23, 2013. Michael Bigham stated, "Abingworth remains a significant shareholder in Supernus but as a matter of general practice we limit the time we spend on the boards of our portfolio companies once they have become public companies." CEO, President and Director of Supernus, Jack Khattar, commented, "Since joining the Supernus Board of Directors in 2006, Michael Bigham has been a great contributor providing the Board with great insight and judgment based on his vast experience in the healthcare industry. We will miss him, and are grateful for his service." The Full Research Report on Supernus Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner